Could Infinity Pharmaceuticals, Inc. (INFI) Lose Strenght? The Stock Increases A Lot Today

March 14, 2018 - By Vivian Park

Investors sentiment decreased to 0.47 in 2017 Q3. Its down 0.16, from 0.63 in 2017Q2. It fall, as 15 investors sold Infinity Pharmaceuticals, Inc. shares while 23 reduced holdings. 6 funds opened positions while 12 raised stakes. 27.30 million shares or 18.05% less from 33.31 million shares in 2017Q2 were reported.
Renaissance Technologies Lc stated it has 0% of its portfolio in Infinity Pharmaceuticals, Inc. (NASDAQ:INFI). Numeric Invsts Lc reported 65,400 shares. Deutsche Bancshares Ag reported 0% in Infinity Pharmaceuticals, Inc. (NASDAQ:INFI). Millennium Management Limited Liability Corporation reported 0% stake. Rock Springs Capital Mgmt L P reported 270,000 shares. Pinnacle Limited accumulated 11,524 shares. Orbimed Advsr Lc accumulated 2.21M shares. Employees Retirement Association Of Colorado invested in 0% or 14,533 shares. Moreover, Tortoise Investment Mngmt has 0% invested in Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) for 100 shares. National Bank & Trust Of Ny Mellon Corp invested 0% of its portfolio in Infinity Pharmaceuticals, Inc. (NASDAQ:INFI). Vanguard Gru owns 2.35M shares. 267,460 were accumulated by Price T Rowe Associates Md. Bridgeway Mngmt invested in 459,000 shares or 0.01% of the stock. Meeder Asset Management Incorporated has invested 0% in Infinity Pharmaceuticals, Inc. (NASDAQ:INFI). Ameriprise Finance holds 0% or 79,010 shares in its portfolio.

Since October 3, 2017, it had 1 buying transaction, and 1 insider sale for $1.99 million activity. Perkins Adelene Q had sold 5,000 shares worth $13,890 on Monday, March 5.

The stock of Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) is a huge mover today! The stock increased 8.91% or $0.22 during the last trading session, reaching $2.69. About 1.14 million shares traded or 41.93% up from the average. Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) has declined 60.96% since March 14, 2017 and is downtrending. It has underperformed by 77.66% the S&P500.
The move comes after 7 months positive chart setup for the $136.41 million company. It was reported on Mar, 14 by We have $2.77 PT which if reached, will make NASDAQ:INFI worth $4.09M more.

Analysts await Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) to report earnings on March, 15 after the close. They expect $-0.27 earnings per share, up 41.30 % or $0.19 from last year’s $-0.46 per share. After $-0.14 actual earnings per share reported by Infinity Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts 92.86 % negative EPS growth.

Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) Ratings Coverage

Among 9 analysts covering Infinity Pharmaceutical (NASDAQ:INFI), 2 have Buy rating, 0 Sell and 7 Hold. Therefore 22% are positive. Infinity Pharmaceutical had 16 analyst reports since August 7, 2015 according to SRatingsIntel. On Tuesday, June 14 the stock rating was downgraded by to “Neutral”. JMP Securities downgraded Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) on Tuesday, June 14 to “Market Perform” rating. The stock of Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) has “Hold” rating given on Monday, August 10 by Zacks. The firm has “Outperform” rating given on Wednesday, March 2 by FBR Capital. The firm has “Neutral” rating given on Tuesday, June 14 by Wedbush. RBC Capital Markets maintained the stock with “Outperform” rating in Friday, August 7 report. RBC Capital Markets downgraded the stock to “Sector Perform” rating in Wednesday, June 15 report. Wells Fargo downgraded the shares of INFI in report on Wednesday, June 15 to “Market Perform” rating. Morgan Stanley downgraded the stock to “Equal-Weight” rating in Wednesday, June 15 report. The firm has “Neutral” rating given on Thursday, February 25 by Wedbush.

Another recent and important Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) news was published by which published an article titled: “Infinity Pharmaceuticals Announces Additions to Board of Directors and …” on March 08, 2018.

Infinity Pharmaceuticals, Inc., a biopharmaceutical company, develops medicines for patients with difficult-to-treat diseases in the United States. The company has market cap of $136.41 million. The Company’s lead product candidate includes IPI-549 an orally administered immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma is in Phase 1 clinical study. It currently has negative earnings. The firm has a license agreement with Verastem, Inc. to research, develop, commercialize, and manufacture duvelisib, a selective inhibitor of the PI3K delta and gamma isoforms, including DUO study that is in randomized Phase III clinical study for patients with relapsed/refractory chronic lymphocytic leukemia and products containing duvelisib; Intellikine, Inc. to discover, develop, and commercialize pharmaceutical products targeting the delta and/or gamma isoforms of PI3K; and Takeda Pharmaceutical Company Limited to develop and commercialize duvelisib.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: